Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30352601 | 0.94 | ALDH1A1 (0.62) | FDPSALDH1A1TSHRPDE4BSMN1; SMN2 | |
| SCHEMBL498127 | 0.94 | ALDH1A1 (0.62) | FDPSALDH1A1TSHRPDE4BSMN1; SMN2 | |
| SCHEMBL2843045 | 0.93 | FDPS (0.61) | FDPSALDH1A1TSHRPDE4BSMN1; SMN2 | |
| SCHEMBL6584890 | 0.90 | ALDH1A1 (0.60) | FDPSALDH1A1TSHRPDE4BSMN1; SMN2 | |
| SCHEMBL6584909 | 0.88 | ALDH1A1 (0.58) | FDPSALDH1A1TSHRPDE4BSMN1; SMN2 | |
| SCHEMBL9733843 | 0.87 | ALDH1A1 (0.57) | FDPSALDH1A1TSHRPDE4BSMN1; SMN2 | |
| SCHEMBL13232716 | 0.85 | DRD2 (0.47) | FDPSALDH1A1TSHRPDE4BSMN1; SMN2 | |
| SCHEMBL14799600 | 0.84 | FDPS (0.47) | FDPSALDH1A1TSHRPDE4BSMN1; SMN2 | |
| SCHEMBL19513039 | 0.84 | POLB (0.58) | ALDH1A1PDE4BSMN1; SMN2MAPTHTT | |
| SCHEMBL17050362 | 0.83 | PDE4B (0.46) | FDPSALDH1A1TSHRPDE4BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383852-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2024-11-21 | — | — | US | disclosed |
| EP-4305022-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2024-01-17 | — | — | EP | disclosed |
| CN-117396462-A | Antiviral compounds | 英菲克斯治疗有限公司 | 2024-01-12 | — | — | CN | disclosed |
| WO-2022189810-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2022-09-15 | — | — | WO | disclosed |
| EP-2283017-B1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-8518955-B2 | Fused pyrimidineone compounds as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-27 | — | — | US | disclosed |
| EP-2626360-A1 | Process for the preparation of fused pyrimidineone compounds useful as TRPV3 modulators | Glenmark Pharmaceuticals S.A. (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-20120115886-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. | 2012-05-10 | — | — | US | disclosed |
| US-20120108813-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. | 2012-05-03 | — | — | US | disclosed |
| US-8119647-B2 | Fused pyrimidineone compounds as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-21 | — | — | US | disclosed |
| EP-2283017-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2011-02-16 | — | — | EP | disclosed |
| US-20090286811-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. | 2009-11-19 | — | — | US | disclosed |
| WO-2009130560-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286811-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV4 | FDPS 523/4885ALDH1A1 3118/4885TSHR 3283/4885 |
| US-20120115886-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV4 | FDPS 523/4885ALDH1A1 3118/4885TSHR 3283/4885 |
| US-20240383852-A1 | ANTI-VIRAL COMPOUNDS | PREP, DNPEP, PLP2 | FDPS 2317/4885ALDH1A1 3785/4885TSHR 4579/4885 |
| US-20120108813-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV4 | FDPS 523/4885ALDH1A1 3118/4885TSHR 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.